WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association® (AdvaMed®), issued the following statement on the Department of Health and Human Services’ (HHS’s) progress on the…
WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association® (AdvaMed®), issued the following statement on CMS’s FY 2020 Inpatient Prospective Payment System (IPPS) final rule:
WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association® (AdvaMed®), issued the following statement on CMS’s release Monday evening of proposed CY 2020 Medicare payment rules…
Contact: Elyse [email protected] WASHINGTON, D.C. – The Advanced Medical Technology Association® (AdvaMed®) today, in light of passage by the U.S. House of Representatives of legislation to repeal the Affordable Care…
LAB Act (H.R. 3584) would delay PAMA reporting period in order to improve data collection process for market-based rates WASHINGTON, D.C. — With 53 million Americans facing steep year-over-year cuts…
Contact: Jon [email protected] The Advanced Medical Technology Association® (AdvaMed®) today announced that Jessica Lenard has joined the association as its Vice President for Government Affairs. “We’re excited to have Jessica…
Calls for Extending Negotiations, Exempting Medical Devices as Alternative Solutions WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association® (AdvaMed®), today sent a letter to U.S.…
WASHINGTON, D.C. – Today the House Ways & Means Committee held a hearing during which members of Congress called attention to a number of crucial policy issues, including repeal of the…
WASHINGTON, D.C. – AdvaMed Accel®, the division of the Advanced Medical Technology Association® (AdvaMed®) focused on issues of concern to smaller medical technology companies, today formally launched a best practices guide designed…
WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association® (AdvaMed®), issued the following statement on release by the U.S. Department of Health and Human Services (HHS) of…